Roche Xeloda Gets Approved For Stomach Cancer In China
This article was originally published in PharmAsia News
Shanghai Roche Pharmaceuticals has received China's State FDA approval for its targeting chemotherapy drug Xeloda (capecitabine) to treat progressive gastric cancer. Research data show that chemotherapy is an important approach for treating gastric cancer, especially for intermediate and advanced cancer. Xeloda is an oral chemotherapy drug first approved in the U.S. It was launched in 2001 for use in China for treating colorectal cancer and metastatic breast cancer. (Click here for more - Chinese Language)
You may also be interested in...
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.
The UK's Celleron has attracted a "blue chip suite of investors" to an Irish-domiciled spin-off based on the potential of Roche-developed emactuzumab for TGCT, a debilitating orphan disease that causes joint damage and has limited clinical options.
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.